HIBCH and neoplasm: Despite our identification of ARhigh tumours experiencing enhanced MitoS scores, patients with metastatic double-negative tumours also possessed a similar level of HIBCH expression, possibly explaining the heightened sensitivity of ARnull PC3 cells to HIBCH inhibition.